Literature DB >> 20062010

Expression of CD133+ cancer stem cells in childhood malignant melanoma and its correlation with metastasis.

Rola Al Dhaybi1, Hervé Sartelet, Julie Powell, Victor Kokta.   

Abstract

Cancer stem cells expressing CD133 exist in a wide array of tumors and their identification in malignant melanoma may help refine classification, diagnosis and treatment. To study the correlation between CD133 expression in childhood melanoma and lymph node and/or visceral metastasis, we evaluated 12 cases of malignant melanoma and 12 control cases of Spitz nevus occurring in children. Double immunostaining with CD133 and Ki-67 was performed in the cases showing CD133 positivity. Three melanoma patients had lymph node metastasis and only one had multivisceral metastases; CD133 was positive only in these four patients. The Ki-67 index was lower in the CD133(+) cells in comparison with the CD133(-) melanoma cells in three cases. We found no positivity for CD133 in all the Spitz nevi. CD133(+) cancer stem cell expression in childhood malignant melanoma might correlate with lymph node and/or visceral metastasis and may have a low proliferative Ki-67 index that might explain their chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20062010     DOI: 10.1038/modpathol.2009.163

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  CD133 expression associated with poor prognosis in ovarian cancer.

Authors:  Jing Zhang; Xiaoqing Guo; Doo Young Chang; Daniel G Rosen; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Mod Pathol       Date:  2011-11-11       Impact factor: 7.842

2.  Characterization of a new human melanoma cell line with CD133 expression.

Authors:  Rosario Gil-Benso; Carlos Monteagudo; Miguel Cerdá-Nicolás; Robert C Callaghan; Sandra Pinto; Alicia Martínez-Romero; Ana Pellín-Carcelén; Teresa San-Miguel; Juan C Cigudosa; Concha López-Ginés
Journal:  Hum Cell       Date:  2012-04-13       Impact factor: 4.174

Review 3.  Lessons from common markers of tumor-initiating cells in solid cancers.

Authors:  Olivier Gires
Journal:  Cell Mol Life Sci       Date:  2011-07-24       Impact factor: 9.261

4.  Correlation of KAI1, CD133 and vasculogenic mimicry with the prediction of metastasis and prognosis in hepatocellular carcinoma.

Authors:  Jing Xu; Yu Zhang; Yichao Wang; Xiaoying Tao; Lili Cheng; Shiwu Wu; Yisheng Tao
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

5.  [Role of ovarian tumor stem-like cells sorted from human epithelial ovarian cancer SKOV3 cells in vasculogenic mimicry formation].

Authors:  Jun Liang; Huimin Xing; Xiaohua Wu; Lei Zhang; Jun Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30

6.  Cancer Stem Cells and Pediatric Solid Tumors.

Authors:  Gregory K Friedman; G Yancey Gillespie
Journal:  Cancers (Basel)       Date:  2011-01-14       Impact factor: 6.639

7.  Sequential expression of putative stem cell markers in gastric carcinogenesis.

Authors:  T Wang; C W Ong; J Shi; S Srivastava; B Yan; C L Cheng; W P Yong; S L Chan; K G Yeoh; B Iacopetta; M Salto-Tellez
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

8.  Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.

Authors:  Chunxia Wang; Jingping Xie; Jiasong Guo; H Charles Manning; John C Gore; Ning Guo
Journal:  Oncol Rep       Date:  2012-08-06       Impact factor: 3.906

9.  CD133 antisense suppresses cancer cell growth and increases sensitivity to cisplatin in vitro.

Authors:  Marisol Blancas-Mosqueda; Pablo Zapata-Benavides; Diana Zamora-Ávila; Santiago Saavedra-Alonso; Edgar Manilla-Muñoz; Moisés Franco-Molina; Carmen Mondragón DE LA Peña; Cristina Rodríguez-Padilla
Journal:  Exp Ther Med       Date:  2012-08-31       Impact factor: 2.447

10.  Immunohistochemical and ultrastructural features of congenital melanocytic naevus cells support a stem-cell phenotype.

Authors:  V A Kinsler; G Anderson; B Latimer; D Natarajan; E Healy; G E Moore; N J Sebire
Journal:  Br J Dermatol       Date:  2013-08       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.